α-Glucosidase-IN-98
α-Glucosidase-IN-98 is a potent orally active α-Glucosidase inhibitor with an IC50 of 18.1 μM. α-Glucosidase-IN-98 reversibly binds with α-Glucosidase via hydrogen bonds, electrostatic interactions and hydrophobic effects, which induces significant conformational alterations in the secondary structure of α-Glucosidase. α-Glucosidase-IN-98 decreases postprandial hyperglycemia in Starch (HY-B2225B)/Sucrose (HY-B1779)-challenged mice. α-Glucosidase-IN-98 can be used for type 2 diabetes mellitus (T2DM) research.
For research use only. We do not sell to patients.
- Formula: C19H19NO3
- Molecular Weight:309.36
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
α‑glucosidase 18.1 μM (IC50) |
In Vitro
α-Glucosidase-IN-98 (compound 5c) maintains strong α-Glucosidase inhibitory activity in the presence of polysaccharides (Acacia gum (HY-N6664), Pectin (HY-W145518)), unlike with proteins, fatty acids, or PEG, which cause significant attenuation[1].
α-Glucosidase-IN-98 (0-40 μM) reversibly inhibits α-Glucosidase via non-covalent interactions, exhibiting a higher binding affinity for the enzyme-substrate complex (Ki = 13.9 μM) than for the free enzyme (Ki = 42.2 μM)[1].
α-Glucosidase-IN-98 binds with α-Glucosidase mainly through hydrogen bonds (with Asp69, Asp352, His280), electrostatic interactions (with Asp215, Asp315), and hydrophobic interactions (with Val216), consistent with the static quenching[1].
α-Glucosidase-IN-98 (0-46.4 μM) reduces the surface hydrophobicity of α-Glucosidase by 29.4%, and induces a structural shift (decreased α-helix, increased β-sheet) that enhances rigidity, suggesting that it can stabilize the enzyme by occupying the hydrophobic cavity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male Kunming mice (7 weeks) with postprandial hyperglycemia induced by acute high-dose (3 g/kg) starch administration[1]
-
Dosage:10, 20 and 40 mg/kg
-
Administration:p.o., single dose
-
Result:Showed dose-dependent hypoglycemic effects.
Demonstrated progressively reduction in glycemic AUCs by 23.4%, 25.7%, and 29.4%, at 10, 20 and 40 mg/kg, respectively.
Resulted in lower blood glucose curves than the control group, demonstrating a notable delay in carbohydrate breakdown and absorption.
-
Animal Model:Male Kunming mice (7 weeks) with postprandial hyperglycemia induced by acute high-dose (3 g/kg) sucrose administration[1]
-
Dosage:10, 20 and 40 mg/kg
-
Administration:p.o., single dose
-
Result:Displayed a dose-dependent decrease in AUC, with reductions of 10.5%, 15.8%, and 21.7%, at 10, 20, and 40 mg/kg, respectively.
Alleviated sucrose-induced postprandial hyperglycemia via α-Glucosidase inhibition.
Chemical Information
-
Molecular Weight 309.36
-
Formula C19H19NO3
-
SMILES
COC1=CC(CCC(CCC2=CC=C(C=C2)C#N)=O)=CC=C1O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)